PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Kowanetz, M.; Koeppen, H.; Zou, W.; Mariathasan, S.; Hellmann, M.; Kockx, M.; Chappey, C.; Kadel, E.; Smith, D.; Miley, N.; Leveque, V.; Funke, R.; Sandler, A.; McCaffery, I.; Amler, L.; Chen, D.; Hegde, P. |
| Abstract Title: | PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell lung cancer (NSCLC) |
| Meeting Title: | CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival |
| Journal Title: | Cancer Immunology Research |
| Volume: | 4 |
| Issue: | Suppl. |
| Meeting Dates: | 2015 Sep 16-19 |
| Meeting Location: | New York, NY |
| ISSN: | 2326-6066 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2016-01-01 |
| Language: | English |
| ACCESSION: | WOS:000375484400017 |
| DOI: | 10.1158/2326-6074.cricimteatiaacr15-a017 |
| PROVIDER: | wos |
| PUBMED: | 27119139 |
| Notes: | Meeting Abstract: A017 -- Source: Wos |
